Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valsartan + hydrochlorothiazide (Lunan Better Pharmaceutical Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Lunan Better Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fuxin is a fixed-dose combination (FDC) medication containing **valsartan** and **hydrochlorothiazide**, developed by **Lunan Better Pharmaceutical Co., Ltd.** for the treatment of mild to moderate primary hypertension. Valsartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, resulting in vasodilation and decreased aldosterone production. Hydrochlorothiazide is a thiazide diuretic that promotes diuresis by inhibiting the sodium-chloride symporter in the distal convoluted tubule of the kidney. This combination therapy is typically utilized when monotherapy with either agent is insufficient to achieve target blood pressure levels, providing a synergistic antihypertensive effect.
- Brand names
- FuxinCo-Diovan
- Other names
- valsartan and hydrochlorothiazide tablets
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on valsartan + hydrochlorothiazide (Lunan Better Pharmaceutical Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valsartan + hydrochlorothiazide (Lunan Better Pharmaceutical Co., Ltd.).